A Case of Pseudomonas mendocina Bacteremia in an Elderly Man With Bilateral Leg Lesions

Ekene U. Ezeokoli 1, Mustafa U. Polat 1, Olusola Ogundipe 2, John Szela 2

1. Infectious Disease, Oakland University William Beaumont School of Medicine, Royal Oak, USA. 2. Infectious Disease, Beaumont Hospital, Royal Oak, USA

Corresponding author: Ekene U. Ezeokoli, ekenex@gmail.com

Abstract

Pseudomonas mendocina is a gram-negative, aerobic, rod-shaped bacterium that rarely causes disease in humans. Documented infections can be severe with varying etiologies, often requiring intensive care. We describe a rare case of bacteremia with P. mendocina in an elderly male, with a comprehensive review of the literature.

An 81-year-old Caucasian male presented with bilateral lower leg erythema and drainage but was afebrile. His past medical history included atrial fibrillation, chronic kidney disease, and congestive heart failure. Labs showed leukocytosis and a blood culture was obtained revealing Pseudomonas mendocina. The pathogen was susceptible to all antibiotics tested and he was successfully treated on cefepime inpatient and a two-week course of ciprofloxacin on discharge.

Our case and literature review presents a successful treatment of a rare cause of bacteremia likely stemming from a soft tissue nidus. P. mendocina has a favorable susceptibility profile and the antibiotics preferred differ from Pseudomonas aeruginosa, a more common pathogen. Worldwide there have been only 18 other documented cases of P. mendocina infection, all successful and with no mortality. Physicians can confidently utilize usual antibiotics in the treatment of this pathogen despite its rare clinical manifestations.

Categories: Internal Medicine, Infectious Disease
Keywords: pseudomonas, mendocina, pseudomonas mendocina, bacteremia, sepsis, ulcers, soft tissue

Introduction

Pseudomonas mendocina is a gram-negative, aerobic, rod-shaped bacterium. It is found naturally in water and soil, with a range of survivability in environments and was first classified in Argentina in 1970 [1]. Human infection is rare, but can be severe and with associated morbidity and mortality. It is ubiquitous in the environment with documented disease in Europe [2], North America [3-5] and Asia [6,7].

Fortunately, P. mendocina has a favorable resistance profile [8]. This is likely at least in part from the absence of selective antimicrobial pressure because of the rarity of human infection. As of the time of literature review, there have only been a handful of documented cases of human P. mendocina infection in the United States. We describe the clinical course of a case of P. mendocina in an adult at a tertiary health care facility.

Case Presentation

An 81-year-old male presented from an extended care facility to the emergency department of our institution with bilateral lower extremity pain, erythema, and swelling. The patient had an extensive medical history including coronary artery disease, atrial fibrillation, systolic and diastolic heart failure with an ejection fraction of 35%, stage 3 chronic kidney disease, diabetes mellitus type 2, and previous strokes. He reported one week of rapid evolution of longstanding lower extremity edema with the development of blisters with oozing sanguineous fluid. He was unaware of any fever episodes but reported chills, nausea, and vomiting whenever he tried to eat. He did report trauma to his lower limbs from falls and had received inconsistent care of his wounds.

At the time of presentation, the patient was hemodynamically stable but with a mild tachycardia with a heart rate of 103. Other vitals were: temperature 97.6°F, blood pressure of 111/59, respiratory rate of 23 with an oxygen saturation of 100% on room air. On physical exam, he appeared nontoxic, alert, and awake. His breathing was non-labored and lungs were clear to auscultation. His cardiac exam, with the exception of tachycardia, was benign, without heave, thrill, gallop or murmur. His left lower extremity was erythematous from the knee and distally, along with multiple bullae and areas of skin desquamation with sanguineous drainage. His right lower limb was also somewhat erythematous but much less so as compared to the left. There was notable tenderness to palpation of both extremities.

Laboratory evaluation revealed leukocytosis with a WBC count of 24,500/mm³, acute kidney injury...
complicating his pre-existing chronic kidney disease as well as a mild lactic acidemia of 3.3. He was diagnosed with sepsis secondary to cellulitis and was admitted. Imaging studies were performed including bilateral venous Doppler which was negative for deep vein thrombosis and superficial thrombophlebitis. Radiographs of the left tibia and fibula showed no fracture, dislocation or bony destruction, but noted diffuse soft tissue swelling. He was started on intravenous vancomycin as dosed by our pharmacy. 2/2 pre-antibiotic blood cultures collected on admission subsequently grew *Pseudomonas mendocina*. An antibiotic susceptibility profile was performed and is summarized in Table 1. Infectious diseases teaching service was consulted, intravenous vancomycin was stopped, and the patient was started on cefepime 2g every 12 hours. Blood cultures were repeated 48 hours after initiation of treatment and were negative. At 72 hours of admission and antibiotic therapy, the patient had significant improvement of leukocytosis with a WBC count down to 15,100/mm³. The patient also received intravenous furosemide for management of heart failure symptoms with improvement of lower limb edema. He was discharged in stable condition to a subacute rehab facility with instructions to complete two weeks of antibiotics therapy with oral ciprofloxacin.

| Antibiotic         | MIC (μg/ml) | Interpretation |
|--------------------|-------------|----------------|
| Cefepime           | <=2         | Susceptible    |
| Ciprofloxacin      | <=1         | Susceptible    |
| Gentamicin         | <=1         | Susceptible    |
| Levofloxacin       | <=0.25      | Susceptible    |
| Piperacillin/Tazobactam | <=4   | Susceptible    |
| Tetracycline       | <=4         | Susceptible    |
| Tobramycin         | <=1         | Susceptible    |

**TABLE 1: Pseudomonas mendocina antibiotic susceptibility in our patient**

MIC: Minimum inhibitory concentration

**Discussion**

*Pseudomonas mendocina* is an uncommon pathogen and is a very rare cause of infection in humans. Our review of literature returned 18 reported cases of *P. mendocina* in humans (Table 2) [8].
| Publication Year | Location    | Age/Sex | Infection type      | Treatment regimen                                      |
|------------------|-------------|---------|---------------------|--------------------------------------------------------|
| 1992 [9]         | Argentina   | 63/Male | Endocarditis        | IV ceftriaxone + IV gentamicin x8 weeks followed by oral ciprofloxacin x2 weeks |
| 2001 [2]         | Denmark     | 28/Female | Endocarditis       | IV gentamicin + IV ampicillin followed by ciprofloxacin |
| 2005 [10]        | Taiwan      | 65/Male | Spondylodiscitis    | IV cefepime x6 weeks, followed by oral ciprofloxacin x4 weeks |
| 2007 [11]        | Turkey      | 36/Male | Endocarditis        | IV cefazidime + IV amikacin x6 weeks                   |
| 2011 [12]        | France      | 79/Female | Endocarditis        | IV piperacillin + IV gentamicin x6 weeks               |
| 2011 [13]        | Israel      | 31/Male | Bacteremia          | IV gentamicin + oral ofloxacin x2 weeks                |
| 2012 [6]         | Singapore   | 86/Female | Osteomyelitis       | N/A                                                    |
| 2013 [7]         | Singapore   | 34/Male | Septic arthritis    | Oral trimethoprim sulfamethoxazole x16 days            |
| 2016 [3]         | United States | 57/Male | Endocarditis        | IV piperacillin/tazobactam x6 weeks                   |
| 2017 [14]        | Portugal    | 22/Male | Peritonitis         | Intraperitoneal cefazolin + intraperitoneal cefazidime followed by oral ciprofloxacin x3 weeks |
| 2018 [15]        | Argentina   | 56/Male | Skin/soft tissue    | Ampicillin sulbactam/colistin                         |
| 2018 [15]        | Argentina   | 36/Male | Skin/soft tissue    | Colistin                                               |
| 2018 [16]        | Taiwan      | 55/Male | Meningitis          | IV ceftriaxone                                        |
| 2018 [16]        | Taiwan      | 66/Female | Meningitis          | IV cefazidime                                         |
| 2018 [16]        | Taiwan      | 79/Male | Meningitis          | IV meropenem                                          |
| 2018 [16]        | Taiwan      | 78/Female | Meningitis          | IV cefepime                                           |
| 2019 [4]         | United States | 63/Male | Bacteremia          | Cefazidime x10 days                                   |
| 2020 [5]         | United States | 72/Male | Bacteremia          | IV piperacillin/tazobactam followed by oral ciprofloxacin x2 weeks |
| This report      | United States | 81/Male | Bacteremia          | IV cefepime followed by oral ciprofloxacin x2 weeks    |

**TABLE 2: Literature on P. mendocina**

Endocarditis (28%), meningitis (22%), and bacteremia (22%) appear to be the most common clinical presentations, but a wide variety of infection sites are possible as noted in Table 2. A systematic review in 2020 by Ioannou and Vougiouklakis [8] describes the literature, with no known cases of death, and the very rare resistance to usual antibiotics.

Our patient presented with bacteremia with a suspected source of infection believed to be his skin lesions with subsequent hematogenous spread. This case adds to the literature of rare human infection with an uncommon organism that was successfully treated and will help advise future clinical approaches to *P. mendocina* infection in humans.

**Conclusions**

*P. mendocina* is an uncommon Gram-negative bacterium implicated in bacteremia, cardiac, central nervous system, skin, and soft tissue infections. Our patient presented with bacteremia likely from hematogenous spread from his lower extremity skin wounds. He was successfully treated and had an uncomplicated clinical course. *P. mendocina* shows sensitivity to most antibiotics except ampicillin. Physicians can confidently utilize usual antibiotics in the treatment of this pathogen despite its rare clinical manifestations.

**Additional Information**

**Disclosures**
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Palleroni NJ, Doudoroff M, Stanier RY, Solanes RE, Mandel M: Taxonomy of the aerobic pseudomonads: the properties of the Pseudomonas stutzeri group. J Gen Microbiol. 1970, 60:215-231. 10.1099/00221287-60-2-215
2. Johannsen HK, Kjeldsen K, Heiby N: Pseudomonas mendocina as a cause of chronic infective endocarditis in a patient with situs inversus. Clin Microbiol Infect. 2001, 7:650-652. 10.1046/j.1198-743x.2001.00331.x
3. Rapsinski GJ, Makadia J, Bhainot N, Min Z: Pseudomonas mendocina native valve infective endocarditis: a case report. J Med Case Rep. 2016, 10:275. 10.1186/s13256-016-1057-6
4. Gani M, Rao S, Miller M, Scoular S: Pseudomonas mendocina bacteremia: a case study and review of literature. Am J Case Rep. 2019, 20:433-436. 10.12659/ajcr.943610
5. Goldberg ME, Blyth M, Swiatlo E: Pseudomonas mendocina bacteremia in a hemodialysis patient with a central venous catheter. Cureus. 2020, 12:e10853. 10.7759/cureus.10853
6. Howe TS, Ehrlich GD, Koh JS, Ng AC, Costerton W: A case of an atypical femoral fracture associated with bacterial biofilm—pathogen or bystander?. Osteoporos Int. 2013, 24:1765-1766. 10.1007/s00198-012-2222-4
7. Chiu LQ, Wang W: A case of unusual Gram-negative bacilli septic arthritis in an immunocompetent patient. Singapore Med J. 2013, 54:164-168. 10.11622/smedj.2013162
8. Ioannou P, Vougiouklakis G: A systematic review of human infections by Pseudomonas mendocina. Trop Med Infect Dis. 2020, 5:71. 10.3390/trropicalmed0500071
9. Aragone MR, Maurizi DM, Clara LO, Navarro Estrada JL, Ascione A: Pseudomonas mendocina, an environmental bacterium isolated from a patient with human infective endocarditis. J Clin Microbiol. 1992, 30:1583-1584. 10.1128/jcm.30.6.1583-1584.1992
10. Chi CT, Lai CH, Fung CP, Wang IH: Pseudomonas mendocina spondylodiscitis: a case report and literature review. Scand J Infect Dis. 2007, 39:615-616. 10.1080/00365540601071883
11. Mert A, Yılmaz M, Ozaras R, Kocak F, Dagdili S: Native valve endocarditis due to Pseudomonas mendocina in a patient with mental retardation and a review of literature. Scand J Infect Dis. 2007, 39:615-616. 10.1080/00365540601071883
12. Suel P, Martin P, Berthelot G, Rohaday S, Etienne M, Chibani A: A case of Pseudomonas mendocina endocarditis (Article in French). Med Mal Infect. 2011, 41:109-110. 10.1016/j.medmal.2010.09.009
13. Neir W, Tabu H, Abid A, Khante J: Pseudomonas mendocina sepsis in a healthy man. Jar Med Assoc J. 2011, 15:375-376.
14. Jerónimo TM, Guedes AM, Stiegsmair S, Guerreiro R, Laranjo C, Bernardo I, Neves PL: Pseudomonas mendocina: the first case of peritonitis on peritoneal dialysis (Article in English, Spanish). Nefrologia. 2017, 37:647-649. 10.1016/j.nefro.2016.11.004
15. Almuzara M, Montaño S, Carulla M, et al.: Clinical cases of VIM-producing Pseudomonas mendocina from two burned patients. J Glob Antimicrob Resist. 2018, 14:273-274. 10.1016/j.jgar.2018.08.002
16. Huang CR, Lien CY, Tsai WC, et al.: The clinical characteristics of adult bacterial meningitis caused by non-Pseudomonas (P.s.) aeruginosa Pseudomonas species: a clinical comparison with Ps. aeruginosa meningitis. Kaohsiung J Med Sci. 2018, 34:49-55. 10.1016/j.kjms.2017.08.007